Not Yet RecruitingPhase 1

Study of IBI3016 in People With Mild or Moderate Hypertension Patients

China30 participantsStarted 2026-05-15

Plain-language summary

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent.
✓. Males or females aged 18 to 75 years. 3 Diagnosed primary hypertension who have not been taking anti-hypertensive medication within 4 weeks prior to informed consent.
✓.Mean sitting SBP ≥140 mmHg and \< 170 mmHg measured by OBPM. 5.Participants able to understand and comply with study procedures.

Exclusion criteria

✕. Known history of secondary hypertension.
✕. Orthostatic hypotension.
✕. Laboratory parameter assessments outside of range at screening：
✕. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
✕. Current or history of intolerance to ACEi and/or ARBs.
✕. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening, or a previous diagnosis of decompensated heart failure or New York Heart Association (NYHA) grade III or IV heart failure.

What they're measuring

Safety indicators-Number of Participants with Adverse Events (AEs)

Timeframe: from baseline to week 12

Trial details

NCT IDNCT07556796

SponsorInnovent Biologics (Suzhou) Co. Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-10-16

Contact for this trial

Andy Guo

0512-69566088 andy.guo@innoventbio.com

View on ClinicalTrials.gov More Hypertension trials